Health & Environmental Research Online (HERO)


Print Feedback Export to File
3858703 
Journal Article 
Disposition of perfluorodecanoic acid in male and female rats 
Vanden Heuvel, JP; Kuslikis, BI; Van Rafelghem, MJ; Peterson, RE 
1991 
Toxicology and Applied Pharmacology
ISSN: 0041-008X
EISSN: 1096-0333 
ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS 
SAN DIEGO 
107 
450-459 
English 
The elimination, tissue distribution, and metabolism of [1-14C]PFDA were examined in male and female rats for 28 days after a single ip dose (9.4 mumol/kg, 5 mg/kg). A sex difference in the fecal elimination of perfluorodecanoic acid (PFDA) was observed with 51 and 24% of the administered 14C being recovered in the feces of male and female rats, respectively, by 28 days post-treatment. The cumulative excretion of PFDA-derived 14C in the urine in 28 days was less than 5% of the administered dose in both sexes. The sex-related difference in the rate of fecal elimination resulted in the observed difference in whole body elimination t1/2 of PFDA in males (t1/2 = 23 days) and females (t1/2 = 45 days). The liver contained the highest concentration of PFDA-derived 14C in both males and females, followed by the plasma and kidneys. The heart, fat pads, testes, and gastrocnemius muscle of males, and the ovaries of females contained much lower concentrations of PFDA. The reason for the high percentage of the ip dose of [1-14C]PFDA in the liver (53% males and 41% females, 2 hr post-treatment) was further examined using an in situ nonrecirculating liver perfusion technique. It was shown that approximately 25% of the [14C]PFDA in the perfusate was extracted by the liver in a single pass. The basis for the sex difference in fecal elimination of PFDA does not appear to be due to a sex difference in biliary excretion. In a 6-hr period, male and female rats with kidneys ligated eliminated essentially the same percentage dose of [14C]PFDA into bile. We had hypothesized that the persistence of PFDA in rats was due to formation of a PFDA-containing lipid (i.e., a [14C]PFDA-containing mono-, di-, or triacylglycerol, cholesteryl ester, methyl ester, or phospholipid). However, no evidence that PFDA is conjugated to form persistent hybrid lipids was obtained, nor were polar metabolites of PFDA detected in urine or bile. In addition, daily urinary excretion of fluoride in male and female rats before and after PFDA treatment was similar, suggesting that the parent compound is not defluorinated. Thus, the disposition of PFDA in male and female rats is characterized by an apparent lack of biotransformation. 
perfluorodecanoic acid; disposition; Toxicology Abstracts; X 24153:Metabolism 
PFAS
• Additional PFAS (formerly XAgency)
• ^Per- and Polyfluoroalkyl Substances (PFAS)
     PFDA (335-76-2)
          Literature Search
               Pubmed
               WOS
               Toxline
• PFAS 150
     Literature Search August 2019
          PubMed
          Web of Science
          ToxNet
     Not prioritized for screening
     Perfluorodecanoic acid
• PFDA
     Literature Search
          Pubmed
          Toxline
          WOS
     Scopus: April 2021
     Screening Results
          Toxicokinetic studies
               ADME
     Title and Abstract Screening
          Tagged as Supplemental
               ADME
               non-PECO route of exposure
     Literature Searches (through April 2023 update and post-public comment/peer review)
          Title & Abstract Screening
               Tagged as Supplemental
                    Full Text Screening
                    In vivo MOA, including non-PECO exposure route
                    ADME
• PFHxS
• PFNA
• Yale PFAS Liver study